Articles related to DEPRESSION

Hormonal conditions like PMDD and menopause can trigger depression; tracking symptoms and using hormone therapy may significantly improve outcomes.

Quetiapine demonstrated superior symptom reduction with significantly lower healthcare costs and higher quality-adjusted life-years compared to lithium in routine clinical practice settings.

“When it comes to trying to work out this issue of sleep problems and depression, it is a classic chicken and the egg problem… The question is, when we look at what’s causing what, that’s not just an idle sort of thing to think about. It has direct treatment implications.”

“Don’t try to think yourself out of a dysregulated state; it’s a body thing.”

Rapid symptom improvement and sustained 4-week benefits distinguish Spravato monotherapy in treatment-resistant depression, with significant MADRS score reductions versus placebo.

The FDA-designated Class II recall affects specific duloxetine lots where exposure may lead to “temporary or medically reversible health consequences or where the probability of serious adverse health consequences is remote.”